Dendrobium officinale polysaccharide demonstrates a sophisticated dual-action mechanism in gut microbiota modulation, functioning both as a broad fermentable substrate for short-chain fatty acid production and as a selective bacterial enrichment agent through specific glycoside hydrolases like GH26 mannanase. The compound's β-(1→4)-glucomannan backbone and optimized mannose/glucose ratio enable targeted expansion of beneficial species including Akkermansia and Parabacteroides while rebalancing the critical Firmicutes/Bacteroidetes ratio. This represents a significant advance in understanding structure-function relationships in prebiotic design. Traditional prebiotics like inulin work through relatively crude fermentation pathways, but this orchid-derived polysaccharide appears to operate more like a molecular key, unlocking specific bacterial metabolic programs. The downstream effects—enhanced SCFA production, improved intestinal barrier function, and modulated TLR4/NF-κB signaling—suggest therapeutic potential across metabolic and neurodegenerative conditions. However, this remains a review synthesizing existing research rather than presenting new clinical data. The precision targeting concept could revolutionize personalized nutrition approaches, though human studies demonstrating clinically meaningful outcomes are still needed to validate these mechanistic insights.